TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
TScan Therapeutics (Nasdaq: TCRX) announced its participation in the Jefferies Global Healthcare Conference, scheduled for June 5, 2024, at 11:00 a.m. ET at the Marriott Marquis in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics (Nasdaq: TCRX) announced its participation in the Jefferies Global Healthcare Conference, scheduled for June 5, 2024, at 11:00 a.m. ET at the Marriott Marquis in New York, NY. The company, which is focused on developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, will present during the conference. A live webcast of the presentation will be available on TScan's website, with a replay accessible for 90 days post-event.
Positive
- TScan Therapeutics will present at a reputable conference, potentially increasing visibility among investors and industry professionals.
- The company's focus on TCR-engineered T cell therapies aligns with a growing field in cancer treatment, which may attract investor interest.
- A webcast of the presentation will be available, providing broader access to stakeholders.
Negative
- No new clinical or financial data was disclosed in the announcement, providing immediate information for investors.
- Participation in conferences often incurs costs without immediate financial return.
- No updates on ongoing trials or business developments were included.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was +1.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will present at the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY on Wednesday, June 5, 2024 at 11:00 a.m. Eastern Time.
A webcast of the presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing TCR-T candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex therapeutic TCR-Ts for patients with a variety of cancers.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.